Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Initially we carried out gap FRAP experiments using the two
2021-09-03

Initially, we carried out gap-FRAP experiments using the two-photon configuration of the confocal microscope. A SR101-positive astrocyte was targeted and a 5 × 5 μm square area was exposed to a laser illumination (5 flashes of 5 s each during 25 s). This procedure resulted in a bleaching of this ast
-
Different from stable transfection transient expression was
2021-09-03

Different from stable transfection, transient expression was also found to yield γ-secretase with robust proteolytic activity []. Co-transfection of all four, but not any three, components of human γ-secretase yielded high expression levels. This observation strongly suggests the co-folding nature o
-
So what makes a FFAR
2021-09-03

So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept
-
The current lack of effective treatments for primary or meta
2021-09-03

The current lack of effective treatments for primary or metastatic UM leaves a large therapeutic gap for patients and clinicians underscoring an urgent need for the identification of additional pharmacological targets for therapeutic intervention. As YAP-targeting strategies have remained elusive th
-
In neurons and neuroendocrine cells the productive fusion pa
2021-09-03

In neurons and neuroendocrine cells, the productive fusion pathway is thought to initiate with the Munc18-1/Syx1 complex (Ma et al., 2013, Hughson, 2013, Lai et al., 2017). The Munc13-1 MUN domain is able to catalyze opening of Syx1 (the transition from the Munc18-1/Syx1 complex to the SNARE complex
-
Several named antagonist ligands have figured noticeably in
2021-09-03

Several named antagonist ligands have figured noticeably in preclinical studies, with proved clear ability to release neurotransmitters and having efficacy in preclinical animal models. Consequently, this has encouraged ongoing research on improved agents with potency, selectivity, and better drug-l
-
The H R couples to G i o proteins and
2021-09-03

The H3R couples to Gαi/o proteins, and hence its stimulation leads to inhibition of adenyalate cyclases, diminishing the level of cyclic AMP (cAMP) with the subsequent reduction in downstream signaling pathways such as protein kinase A (PKA) activation and cAMP-responsive element binding protein (CR
-
br Histamine attenuates the cognitive impairing effects
2021-09-03

Histamine attenuates the cognitive impairing effects of early postnatal maternal deprivation Histamine acting on H2 receptors in the hippocampal CA1 region is able to reverse the deleterious effect of the exposure of rats to partial postnatal maternal deprivation on their memory consolidation of
-
br Conclusion br Introduction Gastric
2021-09-03

Conclusion Introduction Gastric adenocarcinoma (GA) is the fifth most commonly diagnosed malignancy and the third most common cause of death due to cancer worldwide. It is a highly aggressive cancer and 5-year survival rate (5YSR) is usually fatty Wiskostatin synthesis might be one of the cri
-
br We are now ready to
2021-09-03

We are now ready to prove the counterpart of Proposition 6.4 for κ-collectionwise normality. This is the pointfree counterpart of the classical result, originally proved in [23], that κ-collectionwise normality is hereditary with respect to -sets. (It may be worth emphasizing that the localic p
-
These inhibitors possess a cap
2021-09-03

These inhibitors possess a cap group build from cyclization of several amino-acid or non-amino-acid residues, four or more, with one residue bearing an alkyl arm terminated by ZBGs of various types: thiols, ketones or epoxides. In the case of romidepsin 30 (Fig. 7), the thiol group is initially in a
-
br Materials and methods br Results
2021-09-03

Materials and methods Results Discussion Directly modulating specific target proteins and signaling pathways with small-molecule drugs or agonistic ha141 is widely used for cancer metastasis therapies [[39], [40], [41]]. ANXA7 acts as a metastasis suppressor in prostate cancer. However, th
-
Glycogen synthase kinase GSK a serine threonine kinase has
2021-09-03

Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, has been confirmed to be involved in some biological processes in NaCl or wound-treated plants (Chen et al., 2003, Hai et al., 2001, Jonak et al., 2000). NO has been recently recognized as a vital signaling compound in plants. The NO don
-
br Results and discussion br
2021-09-02

Results and discussion Conclusion In this study the first binding assays based on a nonlabelled reporter ligand addressing GlyT1 are described. Following the concept of MS Binding Assays recently introduced in our group, binding of the well-known GlyT1 inhibitor Org24598 employed as reporter l
-
br Materials and methods br Results br Discussion
2021-09-02

Materials and methods Results Discussion All the UDG superfamily glycosylases examined here, UDG, SMUG1, TDGFL, and TDG82−308, are capable of completely converting U-containing duplex substrates to product, though at different rates. Under STO conditions, kobs reflects the slowest kinetic s
14583 records 584/973 page Previous Next First page 上5页 581582583584585 下5页 Last page